A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with veterans of Seattle cell therapy biotechs. Tune Therapeutics is deploying technology that it says can fine-tune the activity of genes in cells. The company has developed a proprietary platform called TEMPO that it calls an “epigenomic therapy,” according to a statement. Epigenomics is a broad term typically applied to the machinery in cells that sticks to DNA and affects gene activity.